Toggle Nav
Product CatalogWebsite Content
1. Purchase larger sizes of common antibodies on established fluorochromes. Packaging and shipping antibodies can be costly. Therefore smaller sizes typically cost greater than two times more compared to larger sizes.
2. Titrate your antibodies for optimal performance in your assay. In the majority of cases you will use a lot less antibody and have better results.
3. Properly ...
Presented by SelectScience
Viral infectious diseases are emerging and re-emerging globally, which underscores the urgent need for accelerated discovery of antiviral therapeutics. Human antiviral monoclonal antibodies (mAbs) are promising drug candidates for...
Meet the scientists on a mission to ensure effective medical countermeasures in the event of a global viral outbreak
From those exposed to Rift Valley Fever in Kenya or Ebola survivors from Liberia or Nigeria, researchers at the Vanderbilt Vaccine Center scour the planet looking for human donors exposed to infectious agents in order to isolate PBMCs, understand as much as possible about B cell responses to pathogens, and ultimately...
Presented by SelectScience
The novel coronavirus SARS-CoV-2 pandemic has brought about an urgency to rapidly develop monoclonal antibodies (mAbs) that neutralize and inhibit this virus. These are the most readily manufacturable therapeutics that can be administered t...
Therapeutic monoclonal antibodies against COVID-19 virus
Monoclonal antibody (mAb) therapeutics have been available for decades, but they are costly to develop and manufacture, and development timelines are too slow to address the rapid rise of novel human pathogens such as SARS-CoV-2. This has highlighted the urgent need for rapid antiviral drug discovery platforms, leading to researchers redeveloping and updating pre...